Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV001509197 | SCV001715780 | uncertain significance | not provided | 2020-06-12 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002359140 | SCV002650886 | uncertain significance | Cardiovascular phenotype | 2019-11-19 | criteria provided, single submitter | clinical testing | The p.R1952L variant (also known as c.5855G>T), located in coding exon 26 of the TTN gene, results from a G to T substitution at nucleotide position 5855. The arginine at codon 1952 is replaced by leucine, an amino acid with dissimilar properties. This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV001509197 | SCV003822145 | uncertain significance | not provided | 2020-05-27 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004528503 | SCV004109476 | uncertain significance | TTN-related disorder | 2023-03-15 | criteria provided, single submitter | clinical testing | The TTN c.5993G>T variant is predicted to result in the amino acid substitution p.Arg1998Leu. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0070% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/2-179640598-C-A). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |